# US 2025/0145941 A1 · Lactobacillus reuteri

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145941 A1
- Document ID: US20250145941A1
- Status: Published application
- Kind: A1
- Application number: 18/949,652
- Filed: 2024-11-15
- Published: 2025-05-08
- Earliest claimed: 2019-09-26
- Assignees: PrecisionBiotics Group Limited
- Applicants: Precisionbiotics Group Limited
- Inventors: Jens WALTER
- Web page: https://patentgrep.com/patent/US20250145941A1

## CPC

- C12N 1/205: Bacterial isolates
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/173: Reuteri
- A61K 2035/115: {Probiotics}
- C12R 2001/225: Lactobacillus
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Lactobacillus reuteri strain having NCIMB accession number 42835 is from a novel phylogenetic clade and has unique immune-stimulatory properties and enhanced ecological performance in the human gut. A substrate for the strain, such as raffinose, may be administered at the same time as or separately from the strain.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A formulation comprising a strain of Lactobacillus reuteri deposited under NCIMB accession number 42835 mixed with an excipient or carrier;
wherein the excipient or carrier comprises a starch, a sugar, an alcohol, silicone, a wax, petroleum jelly, a vegetable oil, polyethylene glycol, propylene glycol, a liposome, gelatin, amylase, magnesium stearate, talc, a surfactant, silicic acid, viscous paraffin, perfume oil, a fatty acid monoglyceride, a fatty acid diglyceride, a petroethral fatty acid ester, hydroxymethyl-cellulose, or polyvinylpyrrolidone; and
wherein the formulation is in the form of a tablet.

### Claim 18 (depends on 17)

The formulation of claim 17, wherein the excipient or carrier comprises lactose.

### Claim 19 (depends on 17)

The formulation of claim 17, further comprising a binder or a coating agent.

### Claim 20 (depends on 17)

The formulation of claim 17, further comprising a substrate chosen from an oligosaccharide or raffinose.

### Claim 21 (depends on 20)

The formulation of claim 20, wherein the substrate comprises a non-digestible oligosaccharide.

### Claim 22

A method of treating a subject to increase gut microbiota diversity, the method comprising administering to the subject a formulation in the form of a tablet comprising Lactobacillus reuteri strain having NCIMB accession number 42835 mixed with an excipient or carrier, wherein the formulation increases the gut microbiota diversity in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the excipient or carrier comprises a starch, a sugar, an alcohol, silicone, a wax, petroleum jelly, a vegetable oil, polyethylene glycol, propylene glycol, a liposome, gelatin, amylase, magnesium stearate, talc, a surfactant, silicic acid, viscous paraffin, perfume oil, a fatty acid monoglyceride, a fatty acid diglyceride, a petroethral fatty acid ester, hydroxymethyl-cellulose, or polyvinylpyrrolidone.

### Claim 24 (depends on 22)

The method of claim 22, wherein the excipient or carrier comprises lactose.

### Claim 25 (depends on 22)

The method of claim 22, wherein the formulation further comprises a binder or a coating agent.

### Claim 26 (depends on 22)

The method of claim 22, wherein the formulation further comprises a substrate chosen from an oligosaccharide or raffinose.

### Claim 27 (depends on 26)

The method of claim 26, wherein the substrate comprises a non-digestible oligosaccharide.

### Claim 28 (depends on 22)

The method of claim 22, wherein the subject is an infant, a young child, a pregnant female, or a mother post childbirth.

### Claim 29 (depends on 22)

The method of claim 22, wherein the formulation increases the growth of microbiota in the subject.

### Claim 30 (depends on 22)

The method of claim 22, wherein the subject has an inflammatory disorder.

### Claim 31 (depends on 22)

The method of claim 22, wherein the formulation is administered as a daily dose of about 1010 viable cells of the strain.
